Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...5960616263646566676869...123124»
  • ||||||||||  Retevmo (selpercatinib) / Eli Lilly, Gavreto (pralsetinib) / Blueprint Medicines, Roche, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Treatment strategy by radioiodine refractory differentiated thyroid cancer (Pubmed Central) -  Apr 26, 2022   
    For this reason, two selective RET inhibitors (selpercatinib, pralsetinib) for differentiated thyroid carcinomas were approved by the FDA in 2020. A new perspective for the future would be the variable re-differentiation strategies, which aim to increase the sensitivity of tumor cells to radioiodine.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Changing Paradigm in Treatment of Differentiated Thyroid Cancer. (Pubmed Central) -  Apr 26, 2022   
    The introduction of THYROPET (124-I PET scan) is gaining momentum as an alternative to 123/131-I scans due to high-resolution images on PET scan increasing the detection sensitivity. All the above factors have resulted in paradigm shift in the management of differentiated thyroid cancer patients.
  • ||||||||||  Baize'an (tislelizumab) / BeiGene, Novartis, Truseltiq (infigratinib) / BridgeBio, Pfizer, Helsinn, Xediton Pharma, Tibsovo (ivosidenib) / Servier
    Journal, PD(L)-1 Biomarker, IO biomarker:  Lactate promotes the growth of patient-derived organoids from hepatopancreatobiliary cancers via ENO1/HIF1α pathway and does not affect their drug sensitivities. (Pubmed Central) -  Apr 22, 2022   
    Peripheral blood mononuclear cells (PBMCs) were isolated and co-cultured with PDOs to test the sensitivity of PDOs to tislelizumab...Furthermore, the addition of lactate did not significantly change the dose-response curves of the PDOs to chemotherapeutic drugs, targeted drugs, and immune checkpoint inhibitor, especially for the drugs to which the cells were sensitive. Thus, lactate can be added to the culture medium of PDOs to promote their growth without altering their genetic profiles and drug sensitivities.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Decoding the mechanism of drugs of heterocyclic nature against hepatocellular carcinoma. (Pubmed Central) -  Apr 21, 2022   
    Conclusion Heterocyclic compounds represent almost two-thirds of the novel drugs approved by FDA between 2010 and 2020 against Cancer. This review summarizes the clinical relevance, mechanism of action, structural activity relationship, and challenges of the seven available anticancer drugs with heterocyclic ring systems against HCC.
  • ||||||||||  oxaliplatin / Generic mfg., lenvatinib / Generic mfg., gemcitabine / Generic mfg.
    SUSTAINED RESPONSE FOR STAGE 4 NEUROENDOCRINE TUMOR WITH GEMCITABINE-OXALIPLATIN-LENVATINIB () -  Apr 20, 2022 - Abstract #ASPHO2022ASPHO_420;    
    The patient was initially switched from this combination to conventional treatment of capecitabine and temozolomide upon correct diagnosis, but was later switched back due to subsequent clinical decline.With this new combination, the patient gained 30 pounds within 2 months, had a volume reduction of the most prominent masses ranging from -35% to -80% and AFP reduction by 64% to 86 ng/mL at 9 weeks. Other than neuropathy warranting replacement of oxaliplatin with carboplatin, this new regimen has been tolerated well and indicates a promising avenue for treatment of recalcitrant and incurable disease.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal:  A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib. (Pubmed Central) -  Apr 20, 2022   
    We report a rare case of a patient with ATC (T4N0M0) who responded extremely well to the administration of lenvatinib after radical surgery. Although ATC is one of the most fatal neoplasms, lenvatinib is a promising drug.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal:  A Case of Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma. (Pubmed Central) -  Apr 20, 2022   
    However, he continued to take lenvatinib for four more months until he complained of dyspnea on exertion. This is a case of lenvatinib-induced interstitial pneumonia that progressed relatively slowly with a long asymptomatic period despite the appearance of pneumonia on image findings.
  • ||||||||||  reozalimab (IBI318) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (clinicaltrials.gov) -  Apr 20, 2022   
    P1,  N=100, Recruiting, 
    This is a case of lenvatinib-induced interstitial pneumonia that progressed relatively slowly with a long asymptomatic period despite the appearance of pneumonia on image findings. Trial primary completion date: Apr 2022 --> Mar 2023
  • ||||||||||  Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
    Review, Journal:  Immunotherapies for hepatocellular carcinoma. (Pubmed Central) -  Apr 19, 2022   
    Furthermore, other cancer immunotherapies, including chimeric antigen receptor T-cells, dendritic cell vaccines and oncolytic viruses are also in early stage clinical trials, for the treatment of advanced HCC. This review will summarise the major approaches that have been and are currently in development for the systemic treatment of advanced HCC, their advantages, drawbacks, and predictions of where this revolutionary treatment field will continue to travel for the foreseeable future.
  • ||||||||||  Journal:  Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. (Pubmed Central) -  Apr 19, 2022   
    Management of advanced thyroid carcinoma has significantly evolved over the last decade thanks to the approval of three multikinase inhibitors, i.e. sorafenib, lenvatinib, cabozantinib, and of two selective RET-tyrosine inhibitors, i.e. selpercatinib and pralsetinib. In this setting, the detection of RET-fusions in advanced thyroid cancer specimens through the use of next-generation sequencing has become a commonly used strategy in clinical practice to select the best treatment options.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer. (Pubmed Central) -  Apr 19, 2022   
    The present review will summarize the conventional management of DTC, the first-line and alternative TKIs in RAIR-DTC, and the approaches that seek to overcome the resistance to MAPK and PI3K pathways' inhibitors. We also aim to emphasize the latest achievements in the research of redifferentiation therapy, immunotherapy, and agents targeting gene rearrangements in advanced DTC.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Frontline therapy for advanced hepatocellular carcinoma: an update. (Pubmed Central) -  Apr 19, 2022   
    Currently approved frontline systemic therapy options include sorafenib, lenvatinib, and atezolizumab/bevacizumab...Based on positive results of randomized phase III HIMALAYA trial, durvalumab and tremelimumab combination could become another frontline option...Frontline systemic therapy is poorly defined in certain subgroups of HCC such as Child-Pugh B and post-transplant recurrent HCC. The landscape of frontline HCC treatment is rapidly changing, and this article reviews the most recent treatment approaches to frontline therapy for advanced HCC.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal, Real-world evidence:  Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study. (Pubmed Central) -  Apr 19, 2022   
    In the first-line treatment of patients with early recurrence after radical resection of HCC, patients treated with TKIs combined with PD-1 therapy has a survival advantage over those treated with TKIs alone. Ascites, HBV DNA positivity, and high levels of AFP often indicate poor efficacy of systemic drug therapy, suggesting that such patients should be closely monitored after surgery and that comprehensive systemic treatment should be administrated in time to improve the prognosis.
  • ||||||||||  adavosertib (AZD1775) / AstraZeneca
    Clinical, Journal:  Efficacy of adavosertib therapy against anaplastic thyroid cancer. (Pubmed Central) -  Apr 15, 2022   
    No appreciable toxicity appeared in mice treated with either single agent or combination treatment. Our findings suggest adavosertib holds the promise for the treatment of patients with anaplastic thyroid cancer.
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
    Journal:  Targeting EML4-ALK gene fusion variant 3 in thyroid cancer. (Pubmed Central) -  Apr 15, 2022   
    He received, after first-line lenvatinib, crizotinib (Drug Rediscovery Protocol (DRUP) trial), and lorlatinib (compassionate use)...To our best knowledge, this is the first reported case describing a patient-specific targeted treatment with lorlatinib based on an EML-ALK gene fusion v3 in a thyroid cancer patient, and own cancer cell line. Tumor-agnostic targeted therapy may provide valuable treatment options in personalized medicine.
  • ||||||||||  Journal:  Systemic therapies for hepatocellular carcinoma: the present and the future. (Pubmed Central) -  Apr 14, 2022   
    After several randomized controlled trials (RCTs) that have attempted to find an effective second-line therapy, regorafenib, cabozantinib, ramucirumab, nivolumab and pembrolizumab represent approved treatments for patients who failed first-line treatment...Moreover, the coexistence of cirrhosis and the competing risk of liver decompensation increase the complexity of the assessment of the net health benefit of the available therapeutic approaches. The aim of this review is to summarize the evidence on systemic treatments for unresectable HCC and to explore the future perspectives on this topic.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. (Pubmed Central) -  Apr 13, 2022   
    Collectively, the data provide the rationale to start lenvatinib at the recommended doses and then interrupt or dose reduce as necessary to achieve required dose intensity for maximized patient benefit. The adverse-event profile of lenvatinib is consistent with that of other tyrosine kinase inhibitors, and clinicians are encouraged to review and adopt relevant symptom-management strategies.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
    Journal, PD(L)-1 Biomarker, IO biomarker:  Therapeutic options in thymomas and thymic carcinomas. (Pubmed Central) -  Apr 13, 2022   
    Although the genomic characteristics of thymic malignancies have been analyzed, few actionable mutations have been detected in general. The development of a treatment strategy using combination pharmacotherapy is anticipated.